Compare Heron Therapeutics Inc (HRTX) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs KB Financial Group, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while KB Financial Group, Inc. trades at $122.58 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 626.7× Heron Therapeutics Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and KB Financial Group, Inc. for 33 Days on average.
| HRTX | KB | |
|---|---|---|
Market Cap | $68.01M | $42.62B |
Volume | 1,891,941 | 164,291 |
Sector | Health | Financials |
52-Week High | $1.49 | $132.88 |
52-Week Low | $0.27 | $77.50 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $174.75M | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
KB Financial Group (KB) trades at $122.00, down 2.19% on the day, with neutral technical signals despite bullish moving averages. The company demonstrates strong fundamental performance with consistent earnings beats, revenue growth from $21.23T in 2025 to $22.37T projected for 2026, and healthy profit margins above 28%. Recent analyst upgrades to Strong Buy highlight momentum potential amid positive South Korean market sentiment.
The stock presents value characteristics with a P/E of 9.68 and P/B below 1.0, supported by robust cash flow generation. However, elevated EV/EBITDA at 21.71 and mixed analyst consensus (33% Buy, 67% Hold) suggest cautious optimism. Key risks include interest rate sensitivity given the banking sector exposure and potential macroeconomic headwinds affecting international operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
